World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
145
Citations
109797
World Ranking
1357
National Ranking
790

Daniel E. Furst publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel E. Furst sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 925 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel E. Furst D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel E. Furst sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 145 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel E. Furst is affiliated with the University of California, Los Angeles in the United States. Their main field of study is Medicine, with a focus on several subfields including Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Rheumatology, Immunology, and Dermatology. This multidisciplinary expertise informs their research approach across a range of related topics.

The scientist's research primarily addresses areas such as:

  • Systemic Sclerosis and Related Diseases
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Mast cells and histamine
  • Dermatologic Treatments and Research
  • Inflammatory Myopathies and Dermatomyositis
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research

Frequent publication venues for Daniel E. Furst include:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Journal of Scleroderma and Related Disorders
  • Arthritis & Rheumatology
  • ACR Open Rheumatology

Their recent published papers illustrate contributions primarily in topics related to systemic sclerosis and interstitial lung disease:

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Respiratory Medicine
  • Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease, 2021, Arthritis & Rheumatology
  • Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial, 2021, American Journal of Respiratory and Critical Care Medicine
  • Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis, 2020, Arthritis & Rheumatology
  • Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management, 2020, Annals of the Rheumatic Diseases

Among frequent coauthors with whom Daniel E. Furst has collaborated are:

  • Dinesh Khanna
  • Marco Matucci-Cerinic
  • Christopher P. Denton
  • Oliver Distler
  • Yannick Allanore

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Jasvinder A. Singh;Kenneth G. Saag;S. Louis Bridges;Elie A. Akl

  • American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

    David T. Felson;David T. Felson;Jennifer J. Anderson;Jennifer J. Anderson;Maarten Boers;Claire Bombardier;Claire Bombardier

  • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

    Michael E. Weinblatt;Edward C. Keystone;Daniel E. Furst;Larry W. Moreland

  • 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

    Jasvinder A. Singh;Daniel E. Furst;Aseem Bharat;Jeffrey R. Curtis

  • American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

    Kenneth G. Saag;Gim Gee Teng;Nivedita M. Patkar;Jeremy Anuntiyo

  • Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

    Daniel O. Clegg;Domenic J. Reda;Crystal L. Harris;Marguerite A. Klein

  • Cyclophosphamide versus placebo in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin

  • Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial

    Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall

  • 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

    Dinesh Khanna;John D. FitzGerald;Puja P. Khanna;Sangmee Bae

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Update of EULAR recommendations for the treatment of systemic sclerosis

    Otylia Kowal-Bielecka;Jaap Fransen;Jerome Avouac;Mike Becker;Mike Becker

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: ACR RA Treatment Recommendations

    Jasvinder A. Singh;Kenneth G. Saag;S. Louis Bridges;Elie A. Akl

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate

    Vibeke Strand;Stanley Cohen;Michael Schiff;Arthur Weaver

  • Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Donald P. Tashkin;Michael D. Roth;Philip J. Clements;Daniel E. Furst

  • American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

    Jennifer M. Grossman;Rebecca Gordon;Veena K. Ranganath;Chad Deal

  • 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

    Dinesh Khanna;Puja P. Khanna;John D. FitzGerald;Manjit K. Singh

  • Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

    J. H. Korn;Maureen D Mayes;M. Matucci Cerinic;M. Rainisio

Frequent Co-Authors

Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Philip J. Clements
Philip J. Clements University of California, Los Angeles
Maureen D. Mayes
Maureen D. Mayes The University of Texas at Austin
Marco Matucci-Cerinic
Marco Matucci-Cerinic University of Florence
Christopher P. Denton
Christopher P. Denton University College London
Virginia D. Steen
Virginia D. Steen Georgetown University
Donald P. Tashkin
Donald P. Tashkin University of California, Los Angeles
Robin Christensen
Robin Christensen University of Southern Denmark
Paul Emery
Paul Emery University of Leeds
Oliver Distler
Oliver Distler University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a future in medicine, there are several flexible and affordable online degree options worth exploring. One popular route is medical billing and coding, which offers a fast entry point into healthcare with programs often spanning just several months. To better understand your options, check the average cost of medical billing and coding program and see how budgeting for these certifications compares to other paths.

Aspiring nurses and nurse practitioners can also benefit from online education. Prospective nurse practitioners can find the cheapest fnp programs online, offering a cost-effective way to advance in the field. If you're just starting out, it's helpful to know how much is online nursing school so you can plan your studies accordingly.

For those aiming high, pursuing a doctoral degree is possible through remote study as well. Accredited phd nursing programs online let you deepen your expertise and expand your career opportunities without sacrificing flexibility.

Best Scientists Citing Daniel E. Furst

Trending Scientists

Recently Published Articles